TipRanks
PharmGen Science, Inc. (KR:004720)
:004720
South Korea Market
004720
PharmGen Science, Inc.
RESEARCH TOOLSreports

PharmGen Science, Inc. (004720) Ratios

― Followers

PharmGen Science, Inc. Ratios

KR:004720's free cash flow for Q2 2026 was ₩0.65. For the 2026 fiscal year, KR:004720's free cash flow was decreased by ₩ and operating cash flow was ₩0.04. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 3.33 2.85 1.69 1.51 1.03
Quick Ratio
 2.41 2.01 1.21 1.18 0.73
Cash Ratio
 0.71 0.65 0.58 0.58 0.28
Solvency Ratio
 -2.94 -2.28 0.07 0.09 0.67
Operating Cash Flow Ratio
 0.63 0.16 0.04 0.09 -0.02
Short-Term Operating Cash Flow Coverage
 49.99 0.97 0.06 0.15 -0.03
Net Current Asset Value
₩ 47.85B₩ 46.96B₩ -3.31B₩ -12.38B₩ -39.74B
Leverage Ratios
Debt-to-Assets Ratio
 <0.01 0.03 0.11 0.11 0.12
Debt-to-Equity Ratio
 <0.01 0.04 0.16 0.17 0.19
Debt-to-Capital Ratio
 <0.01 0.04 0.14 0.14 0.16
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 1.32 1.34 1.46 1.47 1.53
Debt Service Coverage Ratio
 56.05 6.53 0.30 0.27 -0.22
Interest Coverage Ratio
 8.97 4.30 2.56 2.14 2.66
Debt to Market Cap
 <0.01 0.06 0.52 0.36 0.37
Interest Debt Per Share
 51.21 336.62 2.38K 2.59K 2.76K
Net Debt to EBITDA
 -2.19 -1.51 0.10 0.08 1.87
Profitability Margins
Gross Profit Margin
64.26%63.05%63.07%57.68%53.87%
EBIT Margin
2.22%3.46%3.59%5.47%4.91%
EBITDA Margin
4.90%6.09%6.30%8.02%7.14%
Operating Profit Margin
2.22%3.46%6.21%5.47%6.17%
Pretax Profit Margin
-96.69%-87.31%0.59%4.79%59.60%
Net Profit Margin
-76.62%-67.39%1.63%3.43%46.42%
Continuous Operations Profit Margin
-76.62%-67.39%1.63%3.65%46.42%
Net Income Per EBT
79.24%77.19%274.35%71.67%77.88%
EBT Per EBIT
-4350.11%-2524.01%9.56%87.56%965.53%
Return on Assets (ROA)
-72.95%-59.69%0.77%1.70%22.07%
Return on Equity (ROE)
-78.52%-79.73%1.12%2.51%33.82%
Return on Capital Employed (ROCE)
2.49%3.70%3.57%3.35%3.74%
Return on Invested Capital (ROIC)
1.97%2.76%3.16%2.07%2.52%
Return on Tangible Assets
-75.89%-61.84%0.78%1.74%22.51%
Earnings Yield
-213.11%-127.86%3.76%5.57%66.94%
Efficiency Ratios
Receivables Turnover
 3.83 3.90 4.32 4.68 5.38
Payables Turnover
 19.90 24.67 9.55 14.50 14.10
Inventory Turnover
 2.47 2.25 1.99 3.41 3.33
Fixed Asset Turnover
 4.67 4.53 4.41 4.04 3.56
Asset Turnover
 0.95 0.89 0.47 0.50 0.48
Working Capital Turnover Ratio
 2.81 3.21 4.42 9.67 35.05
Cash Conversion Cycle
 224.70 241.25 230.07 159.89 151.48
Days of Sales Outstanding
 95.34 93.54 84.52 77.95 67.80
Days of Inventory Outstanding
 147.71 162.51 183.76 107.12 109.56
Days of Payables Outstanding
 18.34 14.79 38.21 25.17 25.89
Operating Cycle
 243.04 256.04 268.28 185.07 177.36
Cash Flow Ratios
Operating Cash Flow Per Share
 783.27 242.40 131.47 334.09 -82.58
Free Cash Flow Per Share
 675.35 175.69 -22.01 131.89 -850.24
CapEx Per Share
 107.93 66.71 153.48 202.19 767.66
Free Cash Flow to Operating Cash Flow
 0.86 0.72 -0.17 0.39 10.30
Dividend Paid and CapEx Coverage Ratio
 7.26 3.63 0.86 1.65 -0.11
Capital Expenditure Coverage Ratio
 7.26 3.63 0.86 1.65 -0.11
Operating Cash Flow Coverage Ratio
 24.82 0.89 0.06 0.14 -0.03
Operating Cash Flow to Sales Ratio
 0.10 0.03 0.01 0.03 >-0.01
Free Cash Flow Yield
23.92%4.23%-0.54%2.09%-12.65%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -0.46 -0.78 26.55 17.96 1.49
Price-to-Sales (P/S) Ratio
 0.36 0.53 0.43 0.62 0.69
Price-to-Book (P/B) Ratio
 0.45 0.62 0.30 0.45 0.51
Price-to-Free Cash Flow (P/FCF) Ratio
 4.18 23.65 -185.79 47.92 -7.90
Price-to-Operating Cash Flow Ratio
 3.64 17.14 31.11 18.92 -81.38
Price-to-Earnings Growth (PEG) Ratio
 <0.01 <0.01 -0.45 -0.20 0.01
Price-to-Fair Value
 0.45 0.62 0.30 0.45 0.51
Enterprise Value Multiple
 5.08 7.15 6.98 7.77 11.57
Enterprise Value
 43.63B 75.34B 75.25B 103.95B 124.80B
EV to EBITDA
 5.08 7.15 6.98 7.77 11.57
EV to Sales
 0.25 0.44 0.44 0.62 0.83
EV to Free Cash Flow
 2.92 19.53 -188.47 48.41 -9.42
EV to Operating Cash Flow
 2.52 14.16 31.56 19.11 -97.03
Tangible Book Value Per Share
 6.01K 6.35K 13.36K 13.99K 12.90K
Shareholders’ Equity Per Share
 6.33K 6.66K 13.75K 14.02K 13.30K
Tax and Other Ratios
Effective Tax Rate
 0.21 0.23 -1.74 0.28 0.22
Revenue Per Share
 7.93K 7.88K 9.44K 10.24K 9.69K
Net Income Per Share
 -6.07K -5.31K 153.88 351.80 4.50K
Tax Burden
 0.79 0.77 2.74 0.72 0.78
Interest Burden
 -43.50 -25.24 0.17 0.88 12.14
Research & Development to Revenue
 0.04 0.03 0.03 0.03 0.02
SG&A to Revenue
 0.51 0.47 0.42 0.49 0.32
Stock-Based Compensation to Revenue
 0.00 0.00 0.00 0.00 0.00
Income Quality
 -0.13 -0.05 2.34 0.95 -0.01
Currency in KRW